Pheast Therapeutics has begun a phase 1 trial for PHST001, targeting CD24 in advanced solid tumors, to evaluate safety and determine the phase 2 dose. PHST001 has shown promising preclinical results, ...

The biotech set aside a further 10% of its IPO haul for a planned trial of anti-CD24 antibody IMM47. ImmuneOnco revealed (PDF) a shift in its plan after the Hong Kong stock market closed Tuesday.

In 2009, OncoImmune’s founders identified a signal transducer molecule, CD24, which suppresses inflammation by binding to a pattern recognition receptor called Siglec10. They further determined ...